Stock Screener App

Gratuito -

Installare

Drug Manufacturers - Specialty & Generic

1.70

4.24% -0.07

Bioxcel Therapeutics Inc (BTAI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BTAI Giù? Forum Previsione

Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie

BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial - Law360

BioXcel Therapeutics submits sNDA for at-home use of IGALMI By Investing.com - Investing.com South Africa

BioXcel Therapeutics (BTAI) Advances Igalmi's Reach with FDA Sub - GuruFocus

BioXcel Therapeutics submits application to expand IGALMI use for at-home treatment - Investing.com Nigeria

BioXcel seeks FDA approval for at-home IGALMI use - TipRanks

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting - The Manila Times

BioXcel Therapeutics Submits Supplemental NDA To US FDA For IGALMI® At-Home Label Expansion - TradingView

BioXcel Therapeutics submits sNDA for at-home use of IGALMI - Investing.com

BioXcel Therapeutics Submits sNDA for IGALMI® At-Home Use - TradingView

What are the risks of holding BioXcel Therapeutics Inc.Weekly Trade Report & Capital Protection Trading Alerts - bollywoodhelpline.com

How BioXcel Therapeutics Inc. (BX20) stock moves on employment data2025 Fundamental Recap & Weekly Breakout Watchlists - bollywoodhelpline.com

Ag Plus, Inc. - Ag Plus, Inc.

Palmetto Grain Brokerage - Palmetto Grain Brokerage

1 Top Penny Stock to Watch Now - Yahoo Finance

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com

BioXcel adds chief commercial officer as it prepares to expand agitation drug IGALMI’s reach - Hartford Business Journal

VIX Spike: Can BioXcel Therapeutics Inc. stock maintain growth trajectoryTrade Entry Report & Smart Swing Trading Alerts - Bộ Nội Vụ

BioXcel Therapeutics Appoints Mark Pavao as Interim Chief Commercial Officer - citybiz

Returns Recap: Is BioXcel Therapeutics Inc benefiting from interest rate changesJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn

BioXcel Therapeutics names interim CCO amid IGALMI expansion - TipRanks

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting - The Manila Times

BioXcel Therapeutics Announces Interim Chief Commercial Officer - TradingView

Drugmaker taps veteran to pursue at-home treatment for bipolar agitation - Stock Titan

Published on: 2026-01-09 03:25:25 - Улправда

Oklahoma City NewsThe Oklahoman - FinancialContent

Trend Review: How institutional buying supports BioXcel Therapeutics Inc. stockJuly 2025 Spike Watch & Breakout Confirmation Trade Signals - Улправда

Will BioXcel Therapeutics Inc. stock attract ESG investorsQuarterly Portfolio Summary & Consistent Profit Alerts - ulpravda.ru

Is BioXcel Therapeutics Inc. (BX20) stock undervalued historicallyJuly 2025 Breakouts & Fast Moving Stock Trade Plans - Улправда

What insider trading reveals about BioXcel Therapeutics Inc. stockTrade Risk Assessment & Fast Entry Momentum Alerts - ulpravda.ru

How robust is BioXcel Therapeutics Inc. (BX20) stock financial positionMACD Histogram Signals & Maximize Returns With Insights - ulpravda.ru

BioXcel Seeks FDA Nod For At-Home Use Of IGALMI In Bipolar And Schizophrenia Agitation - Nasdaq

BioXcel plans FDA submission for at-home agitation treatment - Investing.com

BioXcel plans FDA submission for at-home agitation treatment By Investing.com - Investing.com Nigeria

BTAI FinancialsIncome Statement - Quiver Quantitative

BioXcel Therapeutics, Inc. Plans Supplemental NDA Submission for IGALMI® Approval for At-Home Use in Treating Agitation Associated with Bipolar Disorders and Schizophrenia - Quiver Quantitative

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI - Chartmill

BioXcel Therapeutics enacts 1-for-16 reverse stock split - MSN

BioXcel Therapeutics (BTAI) price target decreased by 26.17% to 16.12 - MSN

Will BioXcel Therapeutics Inc. stock see insider buying2025 Sector Review & Real-Time Chart Breakout Alerts - Bộ Nội Vụ

Vipin Agarwal Net Worth (2025) - GuruFocus

Is BioXcel Therapeutics Stock Built to Withstand More Downside? - Trefis

What MACD trends signal for BioXcel Therapeutics Inc. (BX20) stockWeekly Market Report & Community Driven Trade Alerts - Улправда

EPS Watch: How robust is BioXcel Therapeutics Inc. (BX20) stock financial position2025 Earnings Surprises & AI Powered Market Entry Strategies - Улправда

Gap Down: Can BioXcel Therapeutics Inc. stock maintain growth trajectoryWeekly Gains Report & Daily Momentum Trading Reports - Улправда

Can BioXcel Therapeutics Inc. stock maintain growth trajectoryEarnings Overview Summary & Verified Swing Trading Watchlist - Улправда

Risk Off: Will BioXcel Therapeutics Inc. stock see insider buying2025 Growth vs Value & AI Driven Stock Reports - Улправда

BioXcel Therapeutics (BTAI) Stock Analysis Report | Financials & Insights - Benzinga

Loss Report: Will BioXcel Therapeutics Inc. stock see insider buyingJuly 2025 Update & Daily Volume Surge Trade Alerts - Улправда

BioXcel Therapeutics Earnings Notes - Trefis

BioXcel Therapeutics holds annual stockholders meeting - MSN

BioXcel Therapeutics Holds Annual Stockholders Meeting - TipRanks

BioXcel Therapeutics (NASDAQ: BTAI) wins approval for reverse stock split plan - Stock Titan

BTAI: All proposals, including director elections and a reverse split amendment, were approved - TradingView — Track All Markets

BioXcel Therapeutics Inc To Host Virtual Roundtable with Leading Medical Experts Transcript - GuruFocus

Aug Decliners: What MACD trends signal for BioXcel Therapeutics Inc BX20 stockJuly 2025 Snapshot & Advanced Swing Trade Entry Alerts - moha.gov.vn

RDY

$13.35

2.66%

ELAN

$24.26

1.46%

NBIX

$136.21

1.92%

RGC

$30.29

3.84%

VTRS

$13.06

0.50%

UTHR

$466.64

2.16%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters